Drug and Alcohol Dependence
Volume 94, Issue 1 , Pages 12-18 , 1 April 2008

Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment

  • Gianluca Quaglio

      Affiliations

    • Medical Service for Addictive Disorders, Department of Internal Medicine, University of Verona, Italy
    • Corresponding Author InformationCorresponding author at: Medical Service for Addictive Disorders, University of Verona, Policlinico GB Rossi, 37134 Verona, Italy. Tel.: +39 045 812 8296; fax: +39 045 812 8290.
    • ,
  • Fabio Lugoboni

      Affiliations

    • Medical Service for Addictive Disorders, Department of Internal Medicine, University of Verona, Italy
    • ,
  • Cristian Pattaro

      Affiliations

    • Unit of Genetic Epidemiology, Institute of Genetic Medicine, EURAC Research, Bolzano/Bozen, Italy
    • ,
  • Barbara Melara

      Affiliations

    • Medical Service for Addictive Disorders, Department of Internal Medicine, University of Verona, Italy
    • ,
  • G.I.C.S.

      Affiliations

    • Group for Scientific Co-operation Between Public Health Authority Centres for Drug Users, Italy
    • Members of GICS active in collecting data include: Roberta Ferrucci, Raffaele Lovaste (Trento); Giovanni Guescini, Anna Ancherani (S. Lazzaro, Bologna); Gianni Canzian, Assunta Russo (Gemona, Udine); Paolo Civitelli (Thiene, Vicenza); Matteo Giordano, Antonio D’Adduzio (Manfredonia, Bari); Claudio Comaschi, Chiara Pieri (Carpaccio, Bologna); Margherita Residori (Villafranca, Verona).
    • ,
  • Paolo Mezzelani

      Affiliations

    • Medical Service for Addictive Disorders, Department of Internal Medicine, University of Verona, Italy
    • ,
  • Don C. Des Jarlais

      Affiliations

    • Edmond de Rothschild Foundation Chemical Dependency Institute, Beth Israel Medical Center, New York City, United States

Received 12 June 2007 ,Revised 20 September 2007 ,Accepted 22 September 2007.

References 

  1. Agresti A. Categorical Data Analysis. 2nd ed.. Hoboken, New Jersey: John Wiley & Sons; 2002;
  2. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med. 1998;60:458–465
  3. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert. Opin. Drug Saf. 2004;5:457–470
  4. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J. Clin. Endocrinol. Metab. 2005;90:203–206
  5. Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. J. Addict. Dis. 2005;24:91–106
  6. Brown R, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad. Med. J. 2004;80:654–659
  7. Cicero TJ, Meyer ER, Miller BT, Bell RD. Age-related differences in the sensitivity of serum luteinizing hormone to prototypic mu, kappa and delta opioid agonists and antagonists. J. Pharmacol. Exp. Ther. 1988;246:14–20
  8. Cushman P. Sexual behaviour in heroin addiction and methadone maintenance. Correlation with plasma luteinizing hormone. N.Y. State J. Med. 1972;72:1261–1265
  9. Daniell HW. Narcotic-induced hypogonadism during therapy for heroin addiction. J. Addict. Dis. 2002;21:47–53
  10. Daniell HW. Sex hormone deficiency in depressed patients receiving opioids. Arch. Intern. Med. 2004;164:804
  11. El-Bassel N, Gilbert L, Rajah V. The relationship between drug abuse and sexual performance among women on methadone. Heightening the risk of sexual intimate violence and HIV. Addict. Behav. 2003;28:1385–1393
  12. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Selected issues 3. Buprenorphine: treatment, misuse and prescription practices. In: Annual Report 2005: the state of the drugs problem in Europe. Lisbon. Available from: http://issues05.emcdda.eu.int.
  13. Hanbury R, Cohen M, Stimmel B. Adequacy of sexual performance in men maintained on methadone. Am. J. Drug Alcohol Abuse. 1977;4:13–20
  14. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin. Endocrinol. 2005;63:381–394
  15. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. 2000;164:371–375
  16. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 2000;343:1290–1297
  17. Johnson SD, Phelps DL, Cottler LB. The association of sexual dysfunction and substance use among a community epidemiological study. Arch. Sex. Behav. 2004;33:55–63
  18. Kokkevi A, Stefanis C. Drug abuse and psychiatric comorbidity. Compr. Psychiatry. 1995;36:329–337
  19. Mendelson JH, Mello NK. Plasma testosterone levels during chronic heroin use and protracted abstinence: study of Hong Kong addicts. NIDA Res. Monogr. 1978;19:142–148
  20. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J. Pharmacol. Exp. Ther. 1975;192:211–217
  21. Mendelson JH, Meyer RE, Ellingboe J, Mirin SM, McDougle M. Effects of heroin and methadone on plasma cortisol and testosterone. J. Pharmacol. Exp. Ther. 1975;195:296–302
  22. National Institute on Drug Abuse (NIDA) . Heroin Abuse and Addiction. Rockville, MD: US Department of Health and Human Services; 2000;(Publication no. 004165)
  23. Negus SS, Picker MJ, Dykstra LA. Kappa antagonist effects of buprenorphine in the rat drug discrimination procedure. NIDA Res. Monogr. 1989;95:518–519
  24. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56–64
  25. Parazzini F, Menchini Fabris F, Bortolotti A, Calabrò A, Chatenoud L, Colli E, et al. Frequency and determinants of erectile dysfunction in Italy. Eur. Urol. 2000;37:43–49
  26. Quaglio GL, Talamini G, Lechi A, Venturini L, Lugoboni F, Des Jarlais DC, et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of seroconversion. Addiction. 2002;97:985–992
  27. Ragni G, De Lauretis L, Bestetti O, Sghedoni D, Gambero V. Gonadal function in male heroin and methadone addicts. Int. J. Androl. 1988;11:93–100
  28. R Development Core Team, 2006. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria.
  29. Risen CB. A guide to taking a sexual history. Psychiatr. Clin. N. Am. 1995;18:39–53
  30. Rosen RC, Riley A, Wagner G, Osterloh IH, Kikpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830
  31. Rosen RC, Lane R, Menza M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol. 1999;19:67–85
  32. Sachs L. Applied Statistics. A Handbook of Techniques. 2nd ed.. New York: Springer-Verlag; 1984;
  33. Seidman SN, Roose SP. The relationship between depression and erectile dysfunction. Curr. Psychiatry Rep. 2000;2:201–205
  34. Spring WD, Willenbring ML, Maddux TL. Sexual dysfunction and psychological distress in methadone maintenance. Int. J. Addict. 1992;27:1325–1334
  35. Strain E, Bigelow G, Liebson I, Stitzer M. Moderate- vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000–1005
  36. Swendsen JD, Merikangas KR. The comorbidity of depression and substance use disorders. Clin. Psychol. Rev. 2000;20:173–189
  37. Teusch L, Scherbaum N, Bohme H, Bender S, Eschmann-Mehl G, Gastpar M. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opioid addicts. Pharmacopsychiatry. 1995;28:84–92
  38. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70:S13–S27
  39. Zung WWK. From art to science: the diagnosis and treatment of depression. Arch. Gen. Psychiatry. 1973;29:328–337

☆ Funding for this study was provided by University of Verona. The University of Verona had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

PII: S0376-8716(07)00428-0

doi: 10.1016/j.drugalcdep.2007.09.025

Drug and Alcohol Dependence
Volume 94, Issue 1 , Pages 12-18 , 1 April 2008

Article Tools